Joaquina Baranda, M.D., leads the KU Cancer Center’s early-phase clinical trial program, which is the first step in taking new therapies from the research lab to the patient
Decades of basic (or bench) science has built the foundational knowledge needed to make advancements in the diagnosis, treatment and prevention of diseases, including cancer. That preclinical research has led to early-phase clinical trials and today’s leading-edge cancer treatments at The University of Kansas Cancer Center.
A cancer diagnosis was never part of Nedra’s plan. But then again, the Kansas City artist, educator and community activist is pretty good at improvising.
When she was diagnosed with triple negative breast cancer – a less common and more aggressive form of breast cancer – her reaction of a simple “OK” left her physician speechless.
“I was uniquely calm. These twists and turns, they are all part of the journey,” Nedra said. “I could have cried and screamed and thrown myself on the floor, but it would not have changed anything, and I would have been behind in my planning.”